Evaxion A/S (EVAX) surged 27.27 percent to $4.20 on Thursday, gaining $0.79, after announcing it has out-licensed its vaccine candidate EVX-B3 to Merck & Co. (MSD) under a previously signed option and license agreement. The deal includes a $7.5 million upfront payment, upto $592 million in potential milestones, and royalties on net sales.
The stock opened at $4.28 and traded between $3.91 and $4.75, compared with a prior close of $3.30 on the Nasdaq.
Trading volume spiked to 71.4 million shares, well above the average of 92,139. Evaxion now trades within a 52-week range of $1.20 to $16.10.
4.2000+0.9000(+27.2727%)
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.